July 31, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring Entellus Medical Inc. (NASDAQ:ENTL) in real time and just received an alert that ENTL is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 26,805,885 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $17.63. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net .
From July 2012 to July 2017, an aggregate amount of 26,805,885 shares of ENTL have been shorted for a total dollar value of $472,672,620. The ENTL SqueezeTrigger price of $17.63 is the volume weighted average price that all shorts are short in shares of ENTL. There is still approximately $30,833,354 of potential short covering in shares of ENTL.
Buyins.net has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.buyins.net .
Entellus Medical Inc. (NASDAQ:ENTL) – Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic and recurrent sinusitis. The company offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its battery power; Light Fiber, a single-use tool that provides real-time trans-illumination of the sinus cavity; Light Seeker, a tool with optical fibers embedded into the device to allow ear, nose, and throat (ENT) physicians to access the frontal sinus and trans-illuminate the sinus cavity; Maxillary Seeker, a tool that allow users to find the correct angle to access the natural maxillary ostia; and Sphenoid Seeker/Freer, a two-in-one tool that enables ENT physicians to navigate access to the sphenoid ostium. In addition, the company offers FocESS Sinuscopes that provide ENT physicians with a solution for endoscopic visualization during a sinus procedure; and MiniFESS family of surgical instruments, which include various devices that enable physicians to perform traditional surgical procedures. Further, it distributes surgical navigation systems, components, parts, and related ancillary products to ENT physicians; and XeroGel Nasal Packing Material for use in patients undergoing nasal or sinus surgery, as well as for use as a nasal packing to treat epistaxis or nasal bleeding. The company offers its products through a direct sales force in the United States and United Kingdom, as well as through distributors worldwide. Entellus Medical, Inc. was founded in 2006 and is headquartered in Plymouth, Minnesota.
The SqueezeTrigger database of billions of short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor – Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new “Fair Market Making Requirements”
Naked Shorts (RegSho) – Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING
Earnings – Predicts probability, price move and length of move before and after all US stock earnings reports
Seasonality – Predicts probability, price move and length of move based on exact time of year for all US stocks
Group Correlation – Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups
SqueezeTrigger – Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Valuation – Tracks all known valuation models and applies them.
GATS – Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies.
PatternScan – Automates tracking of every technical pattern and predicts next move in stocks.
Insider – Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders
Events – Tracks patterns directly correlated to specific events.
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Tom Ronk, CEO